Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
| Հիմնական հեղինակներ: | , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
BMC
2019-07-01
|
| Շարք: | BMC Public Health |
| Խորագրեր: | |
| Առցանց հասանելիություն: | http://link.springer.com/article/10.1186/s12889-019-7303-2 |